Biocardia Inc (BCDA)

Currency in USD
0.929
+0.049(+5.57%)
Closed·
0.886-0.043(-4.63%)
·
BCDA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.8520.948
52 wk Range
0.7502.290
Key Statistics
Prev. Close
0.929
Open
0.88
Day's Range
0.852-0.948
52 wk Range
0.75-2.29
Volume
186.47K
Average Volume (3m)
3.05M
1-Year Change
-50.8519%
Book Value / Share
0.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BCDA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.500
Upside
+1,568.46%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Biocardia Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Neutral
Moving Averages
Strong Buy

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.500
(+1,568.46% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy25.00+2,591.07%-MaintainSep 23, 2025

Biocardia Inc SWOT Analysis


Pivotal Trial Phase
BioCardia's CardiAMP cell therapy system enters critical Phase 3 trial, with potential to revolutionize heart failure treatment amid financial challenges
Regulatory Milestones
FDA protocol amendment and CMS reimbursement approval boost CardiAMP HF II trial, expanding patient eligibility and mitigating study costs
Market Dynamics
Explore BioCardia's position in the competitive cell therapy landscape, with promising early results setting high expectations for cardiovascular treatment
Financial Outlook
Analysts project trial completion by 2025, with price targets ranging from $4 to $25, despite current negative EBITDA and cash burn concerns
Read full SWOT analysis

Biocardia Inc Earnings Call Summary for Q2/2026

  • BioCardia reported Q2 2026 adjusted EPS loss of $0.13, beating analyst estimates of $0.18 loss by 27.78%; shares rose 5.33% after hours.
  • Japan's PMDA endorsed Shonin submission for CardiAMP cell therapy; FDA indicated CardiAMP Heart Failure II trial may support U.S. approval.
  • Net loss narrowed to $1.6M from $2.0M year-over-year; total expenses fell to $1.6M from $2.1M driven by lower R&D spending.
  • Cash position of $5.4M provides runway into 2027; company plans Japan Shonin submission next quarter while continuing U.S. trial enrollment.
  • Stock remains pressured at $0.927, down 46% year-over-year and near 52-week low; low current ratio of 0.41 signals potential liquidity concerns.
Last Updated: 12/08/2026, 22:30
Read Full Transcript

Earnings

Latest Release
Aug 12, 2026
EPS / Forecast
-0.13 / -0.18
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

BCDA Income Statement

Compare BCDA to Peers and Sector

Metrics to compare
BCDA
Peers
Sector
Relationship
P/E Ratio
−1.4x−1.4x−0.4x
PEG Ratio
-−0.050.00
Price/Book
3.9x2.5x2.6x
Price / LTM Sales
-132.4x3.1x
Upside (Analyst Target)
-202.6%48.4%
Fair Value Upside
Unlock22.7%6.5%Unlock

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
265.87K2.34%233.97K
Other Institutional Investors
2.20M19.38%1.94M
Public Companies & Retail Investors
8.90M78.28%7.84M
Total
11.37M100.00%10.01M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Lincoln Alternative Strategies Llc7.03%800,000704
Citigroup Inc.3.50%397,594350

People Also Watch

0.40
RMSG
+5.25%
1.000
QTEX
-0.99%
0.889
OTLK
-19.18%
4.9100
MNTS
+1.03%
1.370
LASE
+7.87%

FAQ

What Is the Biocardia (BCDA) Stock Price Today?

The Biocardia stock price today is 0.929 USD.

What Stock Exchange Does Biocardia Trade On?

Biocardia is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Biocardia?

The stock symbol for Biocardia is "BCDA."

What Is the Biocardia (BCDA) Afterhours Price Today? (Afterhours variable test: 0.945) Current Date: Aug 14, 2026

After hours price: 0.945. After hours price change (units): 0.016. Price change percentage: 1.720%

What Is the Biocardia Market Cap?

As of today, Biocardia market cap is 10.570M USD.

What Is Biocardia's Earnings Per Share (TTM)?

The Biocardia EPS (TTM) is -0.947.

When Is the Next Biocardia Earnings Date?

Biocardia will release its next earnings report on Nov 11, 2026.

From a Technical Analysis Perspective, Is BCDA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Biocardia Stock Split?

Biocardia has split 6 times.

How Many Employees Does Biocardia Have?

Biocardia has 19 employees.

What is the current trading status of Biocardia (BCDA)?

As of Aug 14, 2026, Biocardia (BCDA) is trading at a price of 0.929 USD, with a previous close of 0.929 USD. The stock has fluctuated within a day range of 0.852 USD to 0.948 USD, while its 52-week range spans from 0.750 USD to 2.290 USD.

What Is Biocardia (BCDA) Price Target According to Analysts?

The average 12-month price target for Biocardia is 15.500 USD, with a high estimate of 25 USD and a low estimate of 6 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1,568.46% Upside potential.

What Is the BCDA Premarket Price?

BCDA's last pre-market stock price is 0.886 USD. The pre-market share volume is 9,280.000, and the stock has decreased by -0.043, or -4.630%.

What Is the BCDA After Hours Price?

BCDA's last after hours stock price is 0.945 USD, the stock has decreased by 0.016, or 1.720%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.